Androgen Receptor Monoclonal Antibody (AR 441) | Invitrogen MA5-13426 product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

Androgen Receptor Monoclonal Antibody (AR 441)

catalog :

MA5-13426

quantity :

500 µL

price :

US 524.00

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

AR 441

reactivity :

human, mouse

application :

western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation, chromatin immunoprecipitation, immunohistochemistry - paraffin section

more info or order :

Invitrogen product webpage

citations: 74

Published Application/Species/Sample/Dilution	Reference
western blot; mouse; 1:1000; fig 5c	Gupta A, Mandal K, Singh P, Sarkar R, Majumdar S. Declining levels of miR-382-3p at puberty trigger the onset of spermatogenesis. Mol Ther Nucleic Acids. 2021;26:192-207 pubmed publisher
immunohistochemistry - paraffin section; human; loading ...; fig 3b	Youssef S, El Khateeb E, Aly D, Moussa M. Striae distensae: Immunohistochemical assessment of hormone receptors in multigravida and nulligravida. J Cosmet Dermatol. 2017;16:279-286 pubmed publisher
western blot; human; 1:400; loading ...; fig 3b	Olokpa E, Bolden A, Stewart L. The Androgen Receptor Regulates PPAR? Expression and Activity in Human Prostate Cancer Cells. J Cell Physiol. 2016;231:2664-72 pubmed publisher
western blot; human	Khanna A, Rane J, Kivinummi K, Urbanucci A, Helenius M, Tolonen T, et al. CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations. Oncotarget. 2015;6:19661-70 pubmed
immunohistochemistry; human; 1:200	Elebro K, Butt S, Dorkhan M, Jernstrom H, Borgquist S. Age at first childbirth and oral contraceptive use are associated with risk of androgen receptor-negative breast cancer: the Malmö Diet and Cancer Cohort. Cancer Causes Control. 2014;25:945-57 pubmed publisher
immunohistochemistry; human; 1:2000	Agaimy A, Lell M, Schaller T, Märkl B, Hornung J. 'Neuroendocrine' middle ear adenomas: consistent expression of the transcription factor ISL1 further supports their neuroendocrine derivation. Histopathology. 2015;66:182-91 pubmed publisher
chromatin immunoprecipitation; human	Labbé D, Nowak D, Deblois G, Lessard L, Giguere V, Trotman L, et al. Prostate cancer genetic-susceptibility locus on chromosome 20q13 is amplified and coupled to androgen receptor-regulation in metastatic tumors. Mol Cancer Res. 2014;12:184-9 pubmed publisher
immunohistochemistry - paraffin section; human; 1:100	Lyu S, Yu Q, Ying G, Wang S, Wang Y, Zhang J, et al. Androgen receptor decreases CMYC and KRAS expression by upregulating let-7a expression in ER-, PR-, AR+ breast cancer. Int J Oncol. 2014;44:229-37 pubmed publisher
immunohistochemistry; human; 1:100	Rocha J, Zouanat F, Zoubeidi A, Hamel L, Benidir T, Scarlata E, et al. The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancer. Mol Cell Endocrinol. 2013;381:140-9 pubmed publisher
immunohistochemistry; human	Lottrup G, Jørgensen A, Nielsen J, Jørgensen N, Duno M, Vinggaard A, et al. Identification of a novel androgen receptor mutation in a family with multiple components compatible with the testicular dysgenesis syndrome. J Clin Endocrinol Metab. 2013;98:2223-9 pubmed publisher
western blot; human	Hua S, Yao M, Vignarajan S, Witting P, Hejazi L, Gong Z, et al. Cytosolic phospholipase A2? sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells. Biochim Biophys Acta. 2013;1831:1146-57 pubmed publisher
western blot; human; 1:1000	Choucair K, Guérard K, Ejdelman J, Chevalier S, Yoshimoto M, Scarlata E, et al. The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease Progression. Transl Oncol. 2012;5:453-60 pubmed
western blot; human; 1:1000	Ketola K, Kallioniemi O, Iljin K. Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells. PLoS ONE. 2012;7:e51470 pubmed publisher
immunohistochemistry; human; 1:50	Choucair K, Ejdelman J, Brimo F, Aprikian A, Chevalier S, Lapointe J. PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity. BMC Cancer. 2012;12:543 pubmed publisher
immunohistochemistry; human; 1:100	Park B, Park S, Koo J, Kim S, Park J, Cho J, et al. Homeodomain-interacting protein kinase 1 (HIPK1) expression in breast cancer tissues. Jpn J Clin Oncol. 2012;42:1138-45 pubmed publisher
immunohistochemistry; human; 1:400	McNamara K, Yoda T, Takagi K, Miki Y, Suzuki T, Sasano H. Androgen receptor in triple negative breast cancer. J Steroid Biochem Mol Biol. 2013;133:66-76 pubmed publisher
western blot; human	Chng K, Chang C, Tan S, Yang C, Hong S, Sng N, et al. A transcriptional repressor co-regulatory network governing androgen response in prostate cancers. EMBO J. 2012;31:2810-23 pubmed publisher
immunohistochemistry; human	Lazarevic B, Hammarstrom C, Yang J, Ramberg H, Diep L, Karlsen S, et al. The effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy. Br J Nutr. 2012;108:2138-47 pubmed publisher
chromatin immunoprecipitation; human western blot; human	Lessard L, Labbé D, Deblois G, Begin L, Hardy S, Mes Masson A, et al. PTP1B is an androgen receptor-regulated phosphatase that promotes the progression of prostate cancer. Cancer Res. 2012;72:1529-37 pubmed publisher
immunohistochemistry; human; 1:100	Park S, Park H, Koo J, Yang W, Kim S, Park B. Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers. Breast Cancer Res Treat. 2012;133:311-20 pubmed publisher
western blot; human; 1:1000	Ketola K, Hilvo M, Hyötyläinen T, Vuoristo A, Ruskeepää A, Oresic M, et al. Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. Br J Cancer. 2012;106:99-106 pubmed publisher
western blot; human	Morin A, Fritsch L, Mathieu J, Gilbert C, Guarmit B, Firlej V, et al. Identification of CAD as an androgen receptor interactant and an early marker of prostate tumor recurrence. FASEB J. 2012;26:460-7 pubmed publisher
western blot; human; 1:1000	Vainio P, Wolf M, Edgren H, He T, Kohonen P, Mpindi J, et al. Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration-resistant prostate cancer. Prostate. 2012;72:789-802 pubmed publisher
immunohistochemistry; human	Park S, Koo J, Kim M, Park H, Lee J, Kim S, et al. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol. 2011;22:1755-62 pubmed publisher
western blot; human; 1:1000	Vainio P, Gupta S, Ketola K, Mirtti T, Mpindi J, Kohonen P, et al. Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer. Am J Pathol. 2011;178:525-36 pubmed publisher
immunohistochemistry; human; 1:100	Yu Q, Niu Y, Liu N, Zhang J, Liu T, Zhang R, et al. Expression of androgen receptor in breast cancer and its significance as a prognostic factor. Ann Oncol. 2011;22:1288-94 pubmed publisher
immunohistochemistry; human; 1:50	Claassen H, Schicht M, Brandt J, Reuse K, Schädlich R, Goldring M, et al. C-28/I2 and T/C-28a2 chondrocytes as well as human primary articular chondrocytes express sex hormone and insulin receptors--Useful cells in study of cartilage metabolism. Ann Anat. 2011;193:23-9 pubmed publisher
western blot; human	Moss P, Lyles B, Stewart L. The PPAR? ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells. Exp Cell Res. 2010;316:3478-88 pubmed publisher
immunohistochemistry; human; 1:100	Koo J, Jung W, Jeong J. Metastatic breast cancer shows different immunohistochemical phenotype according to metastatic site. Tumori. 2010;96:424-32 pubmed
western blot; human	Gannon P, Godin Ethier J, Hassler M, Delvoye N, Aversa M, Poisson A, et al. Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancer. PLoS ONE. 2010;5:e12107 pubmed publisher
western blot; human	Chen H, Libertini S, George M, Dandekar S, Tepper C, Al Bataina B, et al. Genome-wide analysis of androgen receptor binding and gene regulation in two CWR22-derived prostate cancer cell lines. Endocr Relat Cancer. 2010;17:857-73 pubmed publisher
immunohistochemistry; human; 1:200	Nodin B, Zendehrokh N, Brändstedt J, Nilsson E, Manjer J, Brennan D, et al. Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival. J Ovarian Res. 2010;3:14 pubmed publisher
western blot; human; 1:400	Singh J, Xie C, Yao M, Hua S, Vignarajan S, Jardine G, et al. Food extracts consumed in Mediterranean countries and East Asia reduce protein concentrations of androgen receptor, phospho-protein kinase B, and phospho-cytosolic phospholipase A(2)alpha in human prostate cancer cells. J Nutr. 2010;140:786-91 pubmed publisher
western blot; human	Chen H, Libertini S, Wang Y, Kung H, Ghosh P, Mudryj M. ERK regulates calpain 2-induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell lines. J Biol Chem. 2010;285:2368-74 pubmed publisher
western blot; human	Waltering K, Helenius M, Sahu B, Manni V, Linja M, Janne O, et al. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res. 2009;69:8141-9 pubmed publisher
western blot; human; 1:1000	Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, Fey V, et al. High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res. 2009;15:6070-8 pubmed publisher
immunohistochemistry; human; 1:200	Yao M, Taylor R, Richards M, Sved P, Wong J, Eisinger D, et al. Prostate-regenerating capacity of cultured human adult prostate epithelial cells. Cells Tissues Organs. 2010;191:203-12 pubmed publisher
immunocytochemistry; human	Vellaichamy A, Sreekumar A, Strahler J, Rajendiran T, Yu J, Varambally S, et al. Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases. PLoS ONE. 2009;4:e7075 pubmed publisher
immunoprecipitation; human	Chen S, Kesler C, Paschal B, Balk S. Androgen receptor phosphorylation and activity are regulated by an association with protein phosphatase 1. J Biol Chem. 2009;284:25576-84 pubmed publisher
western blot; human	Péant B, Diallo J, Dufour F, Le Page C, Delvoye N, Saad F, et al. Over-expression of IkappaB-kinase-epsilon (IKKepsilon/IKKi) induces secretion of inflammatory cytokines in prostate cancer cell lines. Prostate. 2009;69:706-18 pubmed publisher
western blot; human; 1:1000	Bjorkman M, Iljin K, Halonen P, Sara H, Kaivanto E, Nees M, et al. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. Int J Cancer. 2008;123:2774-81 pubmed publisher
western blot; human; 1:200	Urbanucci A, Waltering K, Suikki H, Helenius M, Visakorpi T. Androgen regulation of the androgen receptor coregulators. BMC Cancer. 2008;8:219 pubmed publisher
western blot; human; 1:1000	Wu Y, Li H, Lv X, Wei Q, Li X, Liu X, et al. Overexpression of JKTBP1 induces androgen-independent LNCaP cell proliferation through activation of epidermal growth factor-receptor (EGF-R). Cell Biochem Funct. 2008;26:467-77 pubmed publisher
immunohistochemistry; human; 1:250	Diallo J, Aldejmah A, Mouhim A, Fahmy M, Koumakpayi I, Sircar K, et al. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis. BJU Int. 2008;101:1302-9 pubmed publisher
immunohistochemistry; human	Ponti G, Losi L, Pellacani G, Rossi G, Presutti L, Mattioli F, et al. Wnt pathway, angiogenetic and hormonal markers in sporadic and familial adenomatous polyposis-associated juvenile nasopharyngeal angiofibromas (JNA). Appl Immunohistochem Mol Morphol. 2008;16:173-8 pubmed publisher
western blot; human	Ariazi E, Leitao A, Oprea T, Chen B, Louis T, Bertucci A, et al. Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen. Mol Cancer Ther. 2007;6:2817-27 pubmed
immunohistochemistry; mouse	Compagno D, Merle C, Morin A, Gilbert C, Mathieu J, Bozec A, et al. SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas. PLoS ONE. 2007;2:e1006 pubmed
western blot; human	Libertini S, Tepper C, Rodriguez V, Asmuth D, Kung H, Mudryj M. Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. Cancer Res. 2007;67:9001-5 pubmed
western blot; human	Araki S, Omori Y, Lyn D, Singh R, Meinbach D, Sandman Y, et al. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res. 2007;67:6854-62 pubmed
immunohistochemistry; human; 1:100	Wang W, Bergh A, Damber J. Increased expression of CCAAT/enhancer-binding protein beta in proliferative inflammatory atrophy of the prostate: relation with the expression of COX-2, the androgen receptor, and presence of focal chronic inflammation. Prostate. 2007;67:1238-46 pubmed
western blot; human; 1:200	Konduri S, Schwarz M, Cafasso D, Schwarz R. Androgen receptor blockade in experimental combination therapy of pancreatic cancer. J Surg Res. 2007;142:378-86 pubmed
immunohistochemistry; human; 1:5	Cordon Cardo C, Kotsianti A, Verbel D, Teverovskiy M, Capodieci P, Hamann S, et al. Improved prediction of prostate cancer recurrence through systems pathology. J Clin Invest. 2007;117:1876-83 pubmed
western blot; human	Tepper C, Vinall R, Wee C, Xue L, Shi X, Burich R, et al. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms. Prostate. 2007;67:521-35 pubmed
immunohistochemistry; human	Ejskjaer K, Sørensen B, Poulsen S, Forman A, Nexø E, Mogensen O. Expression of the epidermal growth factor system in endometrioid endometrial cancer. Gynecol Oncol. 2007;104:158-67 pubmed
western blot; human; 1:50	Havens A, Jung Y, Sun Y, Wang J, Shah R, Buhring H, et al. The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis. BMC Cancer. 2006;6:195 pubmed
immunohistochemistry; human	Tanyel F, Yüzbaşioğlu A, Kocaefe C, Orhan D, Ozguc M. Androgen receptor immunostaining and androgen receptor messenger ribonucleic acid expression are increased in cremaster muscles associated with undescended testis. Urology. 2006;67:855-8 pubmed
immunohistochemistry; human; 1:50	Theodoropoulos V, Tsigka A, Mihalopoulou A, Tsoukala V, Lazaris A, Patsouris E, et al. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications. Urology. 2005;66:897-902 pubmed
immunohistochemistry - paraffin section; human; 1:100 immunohistochemistry; human; 1:100	Asioli S, Marucci G, Ficarra G, Stephens M, Foschini M, Ellis I, et al. Polymorphous adenocarcinoma of the breast. Report of three cases. Virchows Arch. 2006;448:29-34 pubmed
immunohistochemistry; human	Ejskjaer K, Sørensen B, Poulsen S, Mogensen O, Forman A, Nexø E. Expression of the epidermal growth factor system in human endometrium during the menstrual cycle. Mol Hum Reprod. 2005;11:543-51 pubmed
immunohistochemistry; human; 1:80 western blot; human; 1:200	Sonneveld E, Jansen H, Riteco J, Brouwer A, van der Burg B. Development of androgen- and estrogen-responsive bioassays, members of a panel of human cell line-based highly selective steroid-responsive bioassays. Toxicol Sci. 2005;83:136-48 pubmed
	Brodzki A, Łopuszyński W, Millan Y, Tatara M, Brodzki P, Kulpa K, et al. Androgen and Estrogen Receptor Expression in Different Types of Perianal Gland Tumors in Male Dogs. Animals (Basel). 2021;11: pubmed publisher
	Liu W, Wang C, Wang S, Zeng K, Wei S, Sun N, et al. PRPF6 promotes androgen receptor/androgen receptor-variant 7 actions in castration-resistant prostate cancer cells. Int J Biol Sci. 2021;17:188-203 pubmed publisher
	Bahnassy S, Thangavel H, Quttina M, Khan A, Dhanyalayam D, Ritho J, et al. Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer. Cell Commun Signal. 2020;18:154 pubmed publisher
	Govindan S, Siraganahalli Eswaraiah M, Basavaraj C, Adinarayan M, Sankaran S, Bakre M. Androgen Receptor mRNA levels determine the prognosis in triple-negative breast cancer patients. BMC Cancer. 2020;20:745 pubmed publisher
	Song H, Sun N, Lin L, Wei S, Zeng K, Liu W, et al. Splicing factor PRPF6 upregulates oncogenic androgen receptor signaling pathway in hepatocellular carcinoma. Cancer Sci. 2020;111:3665-3678 pubmed publisher
	Ludwik K, Sandusky Z, Stauffer K, Li Y, Boyd K, O Doherty G, et al. RSK2 Maintains Adult Estrogen Homeostasis by Inhibiting ERK1/2-Mediated Degradation of Estrogen Receptor Alpha. Cell Rep. 2020;32:107931 pubmed publisher
	Begemann D, Wang Y, Yang W, Kyprianou N. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer. Prostate. 2020;80:926-937 pubmed publisher
	Fletcher C, Sulpice E, Combe S, Shibakawa A, Leach D, Hamilton M, et al. Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer. Oncogene. 2019;: pubmed publisher
	Mounir Z, Korn J, Westerling T, Lin F, Kirby C, Schirle M, et al. ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor. elife. 2016;5: pubmed publisher
	Shah R, Mehra R, Chinnaiyan A, Shen R, Ghosh D, Zhou M, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 2004;64:9209-16 pubmed
	Das D, Shah R, Imperiale M. Detection and expression of human BK virus sequences in neoplastic prostate tissues. Oncogene. 2004;23:7031-46 pubmed
	Nabi G, Seth A, Dinda A, Gupta N. Computer based receptogram approach: an objective way of assessing immunohistochemistry of androgen receptor staining and its correlation with hormonal response in metastatic carcinoma of prostate. J Clin Pathol. 2004;57:146-50 pubmed
	Tepper C, Boucher D, Ryan P, Ma A, Xia L, Lee L, et al. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res. 2002;62:6606-14 pubmed
	Shi X, Ma A, Xia L, Kung H, de Vere White R. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res. 2002;62:1496-502 pubmed

image

image 1 :

image 2 :

image 3 :

product information

Product Type :

Antibody

Product Name :

Androgen Receptor Monoclonal Antibody (AR 441)

Catalog # :

MA5-13426

Quantity :

500 µL

Price :

US 524.00

Clonality :

Monoclonal

Purity :

Protein A/G

Host :

Mouse

Reactivity :

Human

Applications :

Immunocytochemistry: 1:25-1:50, Immunohistochemistry (Paraffin): 1:25, Immunoprecipitation: 1:25-1:50, Western Blot: 1:100-1:200

Species :

Human

Clone :

AR 441

Isotype :

IgG1, kappa

Storage :

4° C

Description :

The androgen receptor (AR) is a member of the steroid-hormone receptor superfamily of nuclear receptors. The receptor is more than 90 kDa and has three major functional domains: the N-terminal domain, DNA-binding domain, and the androgen-binding domain. The androgen receptor is a ligand-activated transcription factor that binds active testosterone (T) and dihydrotestosterone (DHT). Upon binding the hormone ligand, the receptor dissociates from accessory proteins, translocates into the nucleus, dimerizes, and then stimulates transcription of androgen responsive genes. The AR signaling pathway plays a key role in development and function of male reproductive organs, including the prostate and epididymis. AR also plays a role in nonreproductive organs, such as muscle, hair follicles, and brain. Androgen Receptor is a phosphoprotein, and also regulates mitogen-activated protein kinase (MAP kinase). The inhibition of the MEK1/2 pathway correlates directly with a change in phosphorylation state of the androgen receptor. Abnormalities in the AR signaling pathway have been linked to a number of diseases, including prostate cancer, Kennedy's disease, and male infertility. Mutations in this gene are associated with complete androgen insensitivity (CAIS).

Immunogen :

Synthetic peptide corresponding to Human Androgen Receptor aa 299-315

Format :

Liquid

Applications w/Dilutions :

Immunocytochemistry: 1:25-1:50, Immunohistochemistry (Paraffin): 1:25, Immunoprecipitation: 1:25-1:50, Western Blot: 1:100-1:200

Aliases :

AIS; Andr; androgen nuclear receptor variant 2; androgen receptor; androgen receptor (Testicular feminization), same as Tfm; androgen receptor splice variant 4b; Ar; AR8; AR-A; AW320017; DHTR; dihydrotestosterone receptor; HUMARA; HYSP1; KD; NR3C4; Nuclear receptor subfamily 3 group C member 4; RP11-383C12.1; SBMA; SMAX1; TFM; Variant AR45

more info or order :

Invitrogen product webpage